Real World Study of MPM in China

Study Overview
=================
Brief Summary
-----------------
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with atypical clinical manifestations. Most patients with MPM are at an advanced stage at the time of diagnosis, and only a few patients can be cured by radical surgery and other treatment measures. Pemetrexed + cisplatin chemotherapy with or without bevacizumab is still the standard treatment for MPM. In recent years, multimodality therapy including surgery, radiotherapy and chemotherapy have shown certain advantages in improving patient overall survival time. Targeted and immunotherapy may bring breakthroughs in MPM therapy. However, there are still no high-quality evidence-based medical evidence reports on the treatment model and effects of MPM patients in China. Focusing on MPM, we plan to systematically review the relevant scientific literature, confirm relevant scientific research questions, and provide references for related treatments. On this basis, we will estimate MPM incidence and mortality rates from 2014 to 2025 based on the data published by the National Cancer Registry. Meanwhile, a retrospective study cohort was constructed based on the electronic medical record database, and according to the research demand, patients were followed up with their post-discharge survival status to comprehensively describe and analyze the incidence, diagnosis, treatment, and prognosis of MPM patients. Also, exploratory analysis of the therapeutic effects of existing clinical treatments was conducted.

Official Title
-----------------
Real World Study of Diagnosis, Treatment and Prognosis of Malignant Pleural Mesothelioma in China

Conditions
-----------------
Malignant Pleural Mesothelioma, Diagnoses Disease, Treatments, Prognosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically confirmed as malignant pleural mesothelioma Aged over 18 Exclusion Criteria: Follow-up less than 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sun Yat-sen University Cancer Center<br> | |
| hanghai Chest Hospital<br> | |
| Tianjin Cancer Hospital<br> | |
| Fudan University Shanghai Cancer Center<br> | |
| Anhui Cancer Hospital<br> | |
| Shandong Cancer Hospital<br> | |
| Hunan Cancer Hospital<br> | |
| Yunnan Cancer Hospital<br> | |
| Chinese Academy of Medical Sciences<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival is defined as the time from diagnosis to death for any reason or last follow-up | 2-year overall survival | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Progression-free survival is defined as the time from diagnosis to the first event of progression | 2-year progression-free survival | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MPM, Prognosis, Radiotherapy